IGFBP-3 recombinant protein

Human IGFBP-3 Recombinant

Cat. Num. AAA553056

• Purity: >95%, as determined by SDS-PAGE and HPLC
• Synonyms: IGFBP-3; Human IGFBP-3 Recombinant; igfbp3; igfbp-3; IGFBP-3 recombinant protein

• Host: E Coli
• Purity/Purification: >95%, as determined by SDS-PAGE and HPLC
• Form/Format: Recombinant IGFBP3 was lyophilized from a 0.2 um filtered PBS solution.
• Sequence Length: 291

• Domain: Thyroglobulin
• Host Note: Optimized DNA sequence encoding Human IGFBP-3 mature chain was expressed in Escherichia Coli.
• Endotoxin: Endotoxin content was assayed using a LAL gel clot method.; Endotoxin level was found to be less than 0.1 ng/ug (1EU/ug).
• Reconstitution: A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
• Molecular Weight Note: Native human IGFBP-3, generated by the proteolytic removal of the signal peptide; and propeptide,the molecule has a calculated molecular mass of approximately 28 kDa. Recombinant IGFBP-3 is a disulfide-linked monomer protein consisting of 264 amino acid residue subunits, migrates as an approximately 28 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
• Preparation and Storage: The lyophilized protein is stable for at least 2 years from date of receipt at -20 degree C.; Upon reconstitution, this cytokine can be stored in working aliquots at 2 degree - 8 degree C for one month, or at -20 degree C for six months, with a carrier protein without detectable loss of activity. ; ; Avoid repeated freeze/thaw cycles.

Related Product Information for IGFBP-3 recombinant protein

IGFBPs are synthesized in the liver and are produced also by various tumor cell lines and cell types. IGFBPs are high affinity binding proteins for IGF. The major fraction of both types of IGF circulating in the blood are bound non- covalently to these carrier proteins. IGF binding proteins modulate IGF activities by increasing their plasma half lives and by inhibiting or promoting the interactions of IGF with receptors on certain target cells. In addition these binding proteins provide a reservoir for IGF in pericellular spaces. Some IGFBPs also have stimulating effects in vitro and some may inhibit the growth of cells. IGFBP1 is found predominantly in the placenta and the amniotic fluid. The predominant sites of IGFBP1 transcription in the human fetal kidney are those with most active differentiation. Elevated serum levels have been observed in patients with Laron-type dwarfism and Growth hormone deficiency. High serum levels of IGFBP1 are found in newborns and it has been suggested that this could be important in protecting them from hypoglycemia.

Product Categories/Family for IGFBP-3 recombinant protein

Cytokines

References

• randomized gh trial with two different dosages in combination with a gnrh analogue in short sga children: effects on metabolic profile, serum growth hormone, igf-i and IGFBP-3 levels .Eur. J. Endocrinol., Feb 2010; 10.1530/EJE-09-1113.
• nuclear export and mitochondrial and er localization of IGFBP-3 regulates its apoptotic properties .Endocr. Relat. Cancer, Jan 2010; 10.1677/ERC-09-0106.
• association between hepatic steatosis and serum igf1 and IGFBP-3 levels in a population-based sample .Eur. J. Endocrinol., Nov 2009; 161: 705 - 713.
• the expression and function of IGFBP-3 in normal and malignant breast tissue .Anticancer Res, Oct 2009; 29: 3785 - 3790.
• prognostic role of insulin-like growth factor receptor-1 (igfr-1) and insulin-like growth factor binding protein-3 (IGFBP-3) expression in small cell lung cancer .ASCO Meeting Abstracts, May 2009; 27: e22155.